Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 16/20 | 0.52 |
| ▸ | DPP4 | P27487 | 2/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4416007 | 0.87 | GPR119 (0.62) | GPR119DPP4DPP7KCNH2CYP2C9 | |
| SCHEMBL4426169 | 0.87 | GPR119 (0.57) | GPR119DPP4DPP7KCNH2CYP2C9 | |
| SCHEMBL4415925 | 0.80 | GPR119 (0.53) | GPR119KCNH2CYP2C9CYP2C19 | |
| SCHEMBL4416008 | 0.78 | GPR119 (0.44) | GPR119DPP4DPP7KCNH2CYP2C19 | |
| SCHEMBL14640818 | 0.78 | GPR119 (0.46) | GPR119DPP4DPP7KCNH2 | |
| SCHEMBL4415731 | 0.78 | GPR119 (0.57) | GPR119CYP2C9CYP2C19 | |
| SCHEMBL4562543 | 0.76 | GPR119 (0.43) | GPR119CYP2C9CYP2C19 | |
| SCHEMBL4423367 | 0.76 | GPR119 (0.61) | GPR119DPP4TP53 | |
| SCHEMBL4414300 | 0.75 | GPR119 (0.52) | GPR119KCNH2S1PR1CYP2C9CYP2C19 | |
| SCHEMBL4412859 | 0.74 | GPR119 (0.63) | GPR119DPP4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | GPR119, GCGR, GPR27 | GPR119 1/4885DPP4 597/4885DPP7 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.